CYTOPOINT® can reduce itch to help restore quality of life for dogs–and owners1
SOPHIE, female, age 3 years, Golden Retriever
Veterinarian: Dr Liz Hardesty, Murrayhill Veterinary Hospital, Beaverton, OR
Sophie’s chronic canine atopic dermatitis forced her to stop her work as a therapy dog
Presentation and history
Sophie is a trained therapy dog. She and her owner thrived on their twice-weekly visits to a local nursing home, where Sophie engaged with and comforted the residents. Shortly after she turned 2, Sophie developed severe itching focused on her ears. Her feet became inflamed, and she developed hot spots. Several food trials were tried but did not improve Sophie’s condition, and Dr Hardesty diagnosed Sophie with canine atopic dermatitis.
Her diminished energy and hot spots led her owner to reluctantly cancel their regular nursing home visits. In addition, Sophie’s owner wasn’t always able to comply with her medication schedules, and disliked putting ointments on Sophie’s skin.
“When Sophie was bothered by allergies, it was exhausting for her to scratch and to bite. And the quality of her life went from just an exuberant puppy to a young dog with some real issues.” — Rick Sirianni, 6/21/16
Sophie is back to her old self and has returned to her therapy rounds
Dr Hardesty began treating Sophie with APOQUEL® (oclactinib tablet) to manage her atopic dermatitis, with very good results. As soon as Dr Hardesty had access to the new monoclonal antibody therapy (mAb), CYTOPOINT, she switched Sophie to monthly CYTOPOINT injections to make compliance easier for Sophie’s owner.
CYTOPOINT treatment result
After her first CYTOPOINT treatment, Sophie’s condition improved rapidly. Dr Hardesty noted, “it was so nice to do a [1-month] recheck for Sophie and not see some hint of otitis, pododermatitis, or itchiness.”
Sophie has now been receiving CYTOPOINT for approximately 6 months, and continues to do very well. Dr Hardesty reports that seeing Sophie monthly for injections has provided a valuable point of regular contact with Sophie and her owner, allowing her to keep a close eye on Sophie’s overall health.
“When I hurt, she hurts and when she hurts, I hurt. So to see her be pain free and not irritated...has been a profound relief for me. It’s a comfort to know that those days are behind her.” — Rick Sirianni, 6/21/16
Indication:CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.
APOQUEL Indications:Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION:Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, please see the full Prescribing Information.
Reference: 1. Data on file, CYTOPOINT Case Studies, Zoetis Inc.
Testimonials represent individual experience only, and the experiences and opinions may be unique to the patient and the speaker. Individual results may vary considering the unique characteristics of the patient.
This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.